Sistema de Salut de Catalunya
Institut Català de la Salut
[Martín García-Sancho A] Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC, University of Salamanca and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain. [Rodríguez-Pinilla SM] Pathology Department, Hospital Universitario Fundación Jiménez Díaz, CIBERONC, Madrid, Spain. [Domingo-Domenech E] Hematology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain. [Climent F] Pathology Department, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Spain. [Sánchez-Garcia J] Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Hematology Department, Hospital Universitario Reina Sofía, Córdoba, Spain. [López Jiménez J] Hematology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. [Castellvi J] Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2023-10-27T10:38:49Z
2023-10-27T10:38:49Z
2023-10
Peripheral T-cell lymphoma
Limfoma perifèric de cèl·lules T
Linfoma periférico de células T
Nodal peripheral T-cell lymphoma (PTCL) with a T follicular helper phenotype (PTCL-TFH) is a new type of PTCL. We aimed to define its clinical characteristics and prognosis compared to PTCL not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL). This retrospective observational study included 175 patients diagnosed with PTCL between 2008 and 2013 in 13 Spanish sites. Patient diagnosis was centrally reviewed, and patients were reclassified according to the World Health Organization (WHO) 2016 criteria: 21 patients as PTCL-NOS, 55 as AITL and 23 as PTCL-TFH. Median follow-up was 56.07 months (95% CI 38.7–73.4). Progression-free survival (PFS) and overall survival (OS) were significantly higher in patients with PTCL-TFH than in those with PTCL-NOS and AITL (PFS, 24.6 months vs. 4.6 and 7.8 months, respectively, p = 0.002; OS, 52.6 months vs. 10.0 and 19.3 months, respectively, p < 0.001). Histological diagnosis maintained an independent influence on both PFS (hazard ratio [HR] 4.1 vs. PTCL-NOS, p = 0.008; HR 2.6 vs. AITL, p = 0.047) and OS (HR 5.7 vs. PTCL-NOS, p = 0.004; HR 2.6 vs. AITL, p = 0.096), regardless of the International Prognostic Index. These results suggest that PTCL-TFH could have more favourable features and prognosis than the other PTCL subtypes, although larger series are needed to corroborate these findings.
This work was supported by Takeda Farmacéutica España, S.A. The authors received no compensation for writing the manuscript.
Article
Published version
English
Fenotip; Limfomes; Cèl·lules T; DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, T-Cell::Lymphoma, T-Cell, Peripheral; PHENOMENA AND PROCESSES::Genetic Phenomena::Phenotype; ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células T::linfoma de células T periféricas; FENÓMENOS Y PROCESOS::fenómenos genéticos::fenotipo
Wiley
British Journal of Haematology;203(2)
https://doi.org/10.1111/bjh.18941
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
Articles científics - HVH [3439]
